Tg Therapeutics (TGTX) Share-based Compensation (2011 - 2026)

Tg Therapeutics' Share-based Compensation history runs 16 years deep, the most recent figure standing at $21.2 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 32.77% year-over-year to $21.2 million; the TTM figure through Mar 2026 stood at $21.2 million (down 61.32% YoY), while the FY2025 annual figure was $64.7 million, up 39.6% from the prior year.
• Share-based Compensation for Q1 2026 stood at $21.2 million, up from $15.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $42.5 million in Q3 2025, with the low at -$975000.0 in Q2 2022.
• The 5-year median for Share-based Compensation is $12.7 million (2024), against an average of $14.7 million.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation plunged 105.98% in 2022, then soared 1493.03% in 2023.
• Tg Therapeutics' Share-based Compensation stood at $36.6 million in 2022, then sank by 66.44% to $12.3 million in 2023, then increased by 28.22% to $15.7 million in 2024, then declined by 0.51% to $15.7 million in 2025, then jumped by 35.45% to $21.2 million in 2026.
• Business Quant data shows TGTX's Share-based Compensation at $21.2 million in Q1 2026, $15.7 million in Q4 2025, and $42.5 million in Q3 2025.